eSense receives sales boost with VaporSpec order
Published 02-JUL-2019 10:00 A.M.
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Life science company eSense-Lab Ltd (ASX:ESE) has received an additional order from North American partner VaporSpec Inc.
The order is for 10,000 30ml bottles of electronic cigarette liquid (e-juice) and follows a successful test shipment of 500 bottles.
The product will be marketed under VaporSpec’s white label brand and distributed in the US vaping market.
As a backdrop, eSense creates natural plant-based products that heal and delight.
Headquartered in Israel, eSense-Lab combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants.
With multi-disciplinary research and development expertise, the company employs unique reverse engineering capabilities and game-changing techniques that enable re-engineering the chemical composition found in plants and reformulating these for numerous commercial applications.
Cannabis is the first plant eSense is targeting for re-engineering.
eSense is creating a cannabis plant that has all the characteristics of the real thing, but does not contain the psychoactive and more heavily regulated cannabinoid compound.
Strong demand for e-liquids
Also known as e-liquids, e-juice is used for vaporising or “vaping”, and is considered a safer alternative to smoking.
Expressing his satisfaction with this recent order and pointing to the prospect of continued sales success, group chairman Piers Lewis said, “I am extremely pleased to update the market on the continued supply of our products to VaporSpec based on the supply agreement signed earlier this year.
“This is a real vote of confidence and shows the satisfaction and trust that VaporSpec has in our products.
“I look forward to informing the market about the continuation of our activities and successes.”
After receiving and market testing the first shipment of 500 bottles, VaporSpec is continuing to fulfil orders for more e-juice as per the multi-year agreement signed between the e-Sense and VaporSpec.
However, there are signs that eSense has only just dipped its toe in the water in what is already a huge market.
As the following indicates, the e-liquids industry is a fast growing multi-billion dollar market that is expected to increase by approximately 50% to US$50 billion between 2021 and 2025.
A commercial distribution agreement negotiated in February to supply e-juice in the US and Canada called for minimum quantities to increase from 450,000 bottles in the first year to 5 million bottles in year three of the agreement.
VaporSpec is a California-based company distributing wholesale and retail products to the vaping industry.
This order further demonstrates e-Senses’s accelerating commercialisation strategy which has seen the company enter supply agreements with US and UK based entities.
In December, eSense negotiated a commercial agreement with UK-based E-Quits, and following the previous purchase of seven litres of eSense-Lab products, a new shipment of material was ordered by EQuits for distribution in the United Kingdom.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.